Nuveen LLC Purchases New Position in Treace Medical Concepts, Inc. $TMCI

Key Points

• Nuveen LLC has acquired 252,700 shares of Treace Medical Concepts, Inc. (TMCI), valued at approximately $2.12 million, now holding 0.40% of the company.
• The company's shares opened at $7.34, with a market capitalization of $463.69 million and a recent earnings report showing a loss of ($0.28) EPS.
• UBS Group and Stifel Nicolaus have recently downgraded their price targets for TMCI shares, with current consensus ratings reflecting a "Hold" status and a target price of $9.83.

Nuveen LLC purchased a new position in Treace Medical Concepts, Inc. (NASDAQ:TMCI - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 252,700 shares of the company's stock, valued at approximately $2,120,000. Nuveen LLC owned approximately 0.40% of Treace Medical Concepts as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of TMCI. CWM LLC increased its position in Treace Medical Concepts by 126.0% in the first quarter. CWM LLC now owns 8,706 shares of the company's stock worth $73,000 after purchasing an additional 4,853 shares during the period. Bayesian Capital Management LP acquired a new position in Treace Medical Concepts during the fourth quarter worth $77,000. GAMMA Investing LLC lifted its stake in shares of Treace Medical Concepts by 10,236.0% during the 1st quarter. GAMMA Investing LLC now owns 10,336 shares of the company's stock worth $87,000 after buying an additional 10,236 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Treace Medical Concepts in the first quarter valued at about $88,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Treace Medical Concepts in the fourth quarter worth $90,000. Institutional investors own 84.08% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Stifel Nicolaus reduced their price objective on Treace Medical Concepts from $9.00 to $6.00 and set a "hold" rating on the stock in a research note on Friday, August 8th. UBS Group reiterated a "neutral" rating and set a $6.50 price target (down from $8.60) on shares of Treace Medical Concepts in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $9.83.

Treace Medical Concepts Trading Up 0.1%

TMCI stock traded up $0.01 on Wednesday, reaching $7.18. The company's stock had a trading volume of 221,820 shares, compared to its average volume of 393,457. Treace Medical Concepts, Inc. has a 12-month low of $4.54 and a 12-month high of $10.79. The firm has a market cap of $453.56 million, a PE ratio of -9.08 and a beta of 0.71. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.52. The business has a fifty day simple moving average of $6.28 and a two-hundred day simple moving average of $6.94.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01. The company had revenue of $47.39 million during the quarter, compared to the consensus estimate of $47.08 million. Treace Medical Concepts had a negative net margin of 23.01% and a negative return on equity of 46.76%. Treace Medical Concepts has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Treace Medical Concepts, Inc. will post -0.92 EPS for the current year.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.